following a full submission:
guselkumab (Tremfya®) is accepted for restricted use within NHSScotland.
Indication under review: Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
SMC restriction: for patients who have failed to respond to conventional systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contraindication to these treatments.
In two phase III studies, guselkumab was superior to a TNF inhibitor in improving symptoms of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of guselkumab. This advice is contingent upon the continuing availability of the PAS in NHSScotland or a list price that is equivalent or lower.
Download detailed advice372KB (PDF)
- Medicine name:
- guselkumab (Tremfya)
- SMC ID:
- SMC No 1340/18
- Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Submission type
- Date advice published:
- 11 June 2018